Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 11, Number 6, 2006

Long-term changes of prostacyclin secretion in radiation-induced myelopathy

Seied Rabie Mahdavi, Alireza Shirazi, Bagher Minaee, Alireza Nikoofar, Hamid Reza Mirzaee


Background We have previously reported the short-term changes in prostacyclin profi le after irradiation of rat cervical cord.
Aim Present research investigated the long-term changes of prostacyclin content.
Materials/Methods Wistar rats in groups of fi ve were irradiated with doses of 2, 4, 6, 15, 25, 30Gy and a single group of 25 with 35Gy X-rays. After 26 and 39 weeks, prostacyclin content was quantified by 6-keto-prostaglandin-F1a (prostacyclin stabilized metabolite).
Specimens were stained routinely for histological studies.
Results The 50% latent period and effective dose were 14.86±1.16 weeks and 25.66±0.54Gy (p<0.0001), respectively. Average ratios of 6-keto-PG-F1a for doses of 2–30Gy were between 78.33–12.93% and 79.48–99.96% for 26 and 39 weeks, respectively. Prostacyclin level after 35Gy shows approximately a 7:1 ratio in comparison to the control group (p<0.002). Histopathological changes in glial and vascular tissues were diagnosed and scored. Prostacyclin bimodal profile was observed.
Conclusions Radiation can cause complex fluctuations of prostacyclin in association with marked histopathological changes.

Signature: Rep Pract Oncol Radiother, 2006; 11(6) : 273-279


« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.